Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Astellas Acquires Belgium Drug Firm Ogeda
April 4, 2017
- Takeda Consumer Healthcare Spin-Off Now Up and Running
April 4, 2017
- Pfizer Introduces Further Voluntary Recall of EpiPen 0.3 mg in Japan
April 4, 2017
- Alcon Pharma Kicks Off Operations
April 3, 2017
- Pfizer Joins Japan Biosimilar Association
April 3, 2017
- JCR’s BBB-Penetrating Hunter Syndrome Med Now in Clinical Stage
April 3, 2017
- Daiichi Sankyo Evaluating Edoxaban as Antithrombotic Therapy after Catheter Ablation
April 3, 2017
- Takeda, CiRA, RIKEN to Begin iPS-Based Research to Discover NGLY1 Deficiency Drug
April 3, 2017
- Daiichi Sankyo Files Public Knowledge-Based Application for Ovisot’s Add’l Indication
April 3, 2017
- EA Pharma Eager to Roll Out Several New Drugs in Next Couple of Years
April 3, 2017
- Orencia Filed for Juvenile Idiopathic Arthritis: BMS, Ono
March 31, 2017
- Takeda’s Dengue Vaccine Candidate Delivers Positive PII Data
March 31, 2017
- Nippon Shinyaku Gets Japan Rights to Jazz Pharma’s Defitelio and Vyxeos
March 31, 2017
- EA Pharma Earns Global Rights to Calypso’s IBD Candidate
March 31, 2017
- Oncolys Joins Hands with Osaka Univ. on Development of Next Generation Telomelysin
March 31, 2017
- Oncolys Teams up with Washington Univ. Biotech Startup
March 31, 2017
- Japan Enrollment Begins for PIII Trial for BACE inhibitor Elenbecestat: Eisai
March 30, 2017
- Tokyo Prosecutors File Appeal in Diovan Case
March 30, 2017
- Nippon Kayaku’s Remicade Biosimilar Approved for Additional Dosage for Psoriasis
March 30, 2017
- Mitsubishi Tanabe, Daiichi Sankyo Expand Tie-Up to Push DPP-4/SGLT-2 Combo
March 30, 2017
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…